The Regulations Amending the Food and Drug Regulations (Labelling, Packaging and Brand Names of Drugs for Human Use) – more commonly known as the "Plain Language Labelling amendments" – came into force on June 13, 2015. The provisions now in force apply to prescription drug products and those that are obtained through a healthcare professional. The plain language requirements for non-prescription products will come into force in 2017.
We have previously reported on the changes to pharmaceutical naming rules and the new plain language labelling regulations in an earlier Pharma in brief.
Health Canada introduced the regulatory amendments in July 2014 as part of its Regulatory Transparency and Openness Framework and its commitment to make information more readily available to Canadians. The Plain Language Labelling amendments aim to improve the safe use of drugs and help reduce preventable harms from medication errors by making drug labels and safety information easier to read and understand. These regulatory amendments also bring Canadian drug labelling requirements in line with international standards, namely the United States and Europe.
Plain language labelling
The Plain Language Labelling amendments include five core requirements that prescription drug manufacturers must comply with during the pre-market submission period. The five requirements are as follows:
- Compliance with plain language labelling provisions that explicitly link the readability of the product label to the factors such as clear writing, color contrast, font size and layout. See section A.01.017 of the Food and Drug Regulations (C.R.C., c. 870) ("FDR").
- Submission of a full mock-up of the product label and packaging intended to be used for the sale of the product. The submission allows Health Canada to review an accurate representation of what the product will look like when it becomes available in the Canadian market in advance of approval. See FDR sections C.01.014.1(2)(m.1) and C.08.002(2)(j.1).
- The requirement to include the contact information of someone who is responsible for the product in Canada should a patient experience a problem, or have a question or concern about the drug product. See FDR section C.01.004.01(1).
- Submission of a Look-alike Sound-alike (also referred to as "LASA") assessment of the proposed product name. See FDR sections C.01.014.1(2)(o) and C.08.002(2)(o). Similarities between product names can cause health care professionals and patients to confuse one product for another, and can result in prescribing errors, transcription errors, dispensing errors and/or patient self-selection errors. The mandatory LASA assessment helps to ensure that the drug brand name will not be confused with another drug's brand, common or proper name due to similar sounding or looking names.
- For non-prescription products, the inclusion of a standard drug information table which must contain information such as indications or uses, recommended doses, route of administration, storage conditions, a list of medicinal and non-medicinal ingredients, and contact information to allow patients to report problems. See FDR section C.01.004.02(1).
In order to provide support and direction to manufacturers on how to comply with the plain language requirements and establish details respecting the amendments, Health Canada has created various policies and guidance documents, such as, "Guidance Document Labelling of Pharmaceutical Drugs for Human Use" (January 2014), the "Guidance Document for Industry – Review of Drug Brand Names" (Released July 2, 2014, effective June 13, 2015) which is now fully implemented, and the "Good Label and Package Practices Guide" which is currently in draft form. As the plain language labelling requirements are implemented, Health Canada will likely provide for further guidance to help manufacturers design safe and clear labels to establish consistent practices across the industry.
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.